“Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s10, https://doi.org/10.25251/skin.1.supp.9.